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Autosomal dominant polycystic kidney disease (ADPKD) is the most common 
inherited kidney disease, with a prevalence of approximately 3-4 per 10.000 in the 
general population, and is characterized by progressive cyst formation in both kidneys 
and renal function loss (1). It is the fourth most common cause of end-stage renal 
disease (ESRD) for which renal replacement therapy has to be started (2). Up to 2015 
there was no treatment option available to slow disease progression, but recently a 
vasopressin V2 receptor antagonist (tolvaptan) has been approved for this indication 
by the European Medicines Agency (3). Beyond decline of renal function and renal 
cyst growth, patients may experience other symptoms such as pain, gastrointestinal 
discomfort and polyuria (4). Although these symptoms are common in ADPKD 
patients, they attain little attention and their consequences may be underestimated 
by physicians.
Renal and liver anatomy and sensory innervation 
The kidneys are retroperitoneal structures that are located at the level of the transverse 
processes of vertebrae thoracic 12 to lumbar 3, with the left kidney being positioned 
somewhat higher than the right. The kidney is surrounded by dense fibrous tissue, 
the renal capsule, which itself is surrounded by perirenal fat. This perinephric fat is 
encapsulated by a thin connective tissue sheath, known as Gerota’s fascia. A normal 
kidney has a length of approximately 10–14 cm and a volume of 150 mL (5). In ADPKD, 
however, the kidneys can be extremely enlarged due to cyst formation, with a single 
kidney volume increasing up to 6,000 mL (6) (Figure 1). In this latter case the kidney 
reaches into the pelvic cavity. The majority of patients develop cysts in the liver as well. 
On radiological imaging liver cysts were found in 94% of ADPKD patients older than 
35 years (7). Most patients do not experience symptoms of their liver cysts, but liver 
enlargement and increased renal volume add both to a high intra-abdominal volume, 
that can lead to gastrointestinal symptoms as regurgitation, nausea and early satiety 
(8). Patients show a considerable variability in liver volume from 1,500 mL up to 14,000 
mL (Figure 1).
In general, sensory innervation of internal organs travels by sympathetic and 
parasympathetic fibers. Nociceptive information from the thoracic, abdominal and 
pelvic organs reaches the spinal cord via sympathetic pathways, whereas those structures 
that bypass the pelvic floor convey the nociceptive impulses via parasympathetic 
pathways. As a consequence, sympathetically and parasympathetically conveyed 
nociception ends in the spinal cord segments C8-L1 and S2-4, respectively (5). In this 
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way, the levels of segmental sensory innervation determine to which dermatomal areas 
visceral pain is referred.
Pain originating from the upper abdominal organs, including the liver, reaches the 
spinal cord (levels T5 – T9), via the celiac plexus, the major splanchnic nerves and 
the sympathetic trunk, respectively (9, 10). Pain originating from the kidneys reaches 
the spinal cord (levels T10-L1) via the nerve plexus surrounding the renal artery, the 
aorticorenal plexus, the lesser and least splanchnic nerve and the sympathetic trunk, 
respectively (10). Small nerve connections between the renal plexus and celiac plexus 
have been reported, indicating that the sensory nerve supply is complex and can 
overlap.
Figure 1. In ADPKD the kidneys and liver can be extremely enlarged due to cyst formation, with a 
single kidney volume increasing up to 6,000 mL and a liver volume up to 14,000 mL.
Natural course of ADPKD
Mutations in the PKD-1 and PKD-2 genes, that encode for the proteins polycystin-1 and 
polycystin-2 respectively, account for most ADPKD cases (11, 12). Mutations in the PKD-
1 gene (located on chromosome 16p13.3) account for 85% and mutations in the PKD-2 
gene (located on chromosome 4q21) for 15% of the ADPKD cases where a mutation 
has been found (11, 12). At present, no mutation can be identified in approximately 
10% of patients. Mutations can be distinguished in truncating (frameshift, nonsense, 
splice mutations and large rearrangements) and non-truncating mutations (in frame 
and missense mutations). The PKD-1 gene is adjacent to a disease gene for tuberous 
sclerosis (TSC-2), a disorder that is characterized primarily by renal angiomyolipomas 
and renal cysts. Deletions of both the PKD-1 and TSC-2 genes are rare, but cause a 
severe form of ADPKD (13). Mutation penetrance in ADPKD is 100%. A child of an 
affected ADPKD patient has therefore a 50% risk to inherit and develop ADPKD. In 
5-10% of the cases, there is no family history of ADPKD, and in such cases the disease 




Cyst formation leads to massively enlargement of both kidneys and distortion of 
the renal architecture. By glomerular hyperfiltration the kidneys compensates for the 
progressive loss of glomeruli, but after sometimes considerable length of time renal 
function starts to decline, and ultimately approximately 70% of the patients reaches 
end-stage renal disease between the age of 40-70 years (7). Peritoneal dialysis is not 
contraindicated in ADPKD patients, unless the kidneys are extremely enlarged (14). 
Sometimes nephrectomy of the native polycystic kidney is needed to assure enough 
space in the iliac fossa for a renal allograft (15). 
The natural course of the disease with respect to loss of kidney function has a 
substantial variability within and between affected families (16). Factors positively 
associated with disease severity are PKD1 mutations (particularly truncating 
mutations), male sex, and early onset of hypertension and urological symptoms, such 
as macroscopic hematuria, recurrent urinary tract infections and renal stones (17). High 
total kidney volume, greater than expected for a given age, also signifies rapid disease 
progression (18-20). Laboratory markers that are associated with worse prognosis 
include overt proteinuria, macroalbuminuria, and elevated plasma copeptin levels (21, 
22). All these markers may help to identify ADPKD patients who are most likely to have 
rapid disease progression and thus may benefit most from early disease modifying 
interventions.
Diagnosis and screening
At present the diagnosis of ADPKD can easily be made by radiological imaging. The 
implications of a positive diagnosis should be discussed before testing. The diagnosis 
ADPKD could for instance lead to an increase in insurance costs and some patients 
experience a negative psychological impact. Typical findings on radiological imaging 
include large kidneys and extensive cysts scattered throughout both kidneys. Because 
of costs and safety, ultrasound is the method of first choice. At the moment the Ravine 
criteria adjusted by Pei are used to diagnose ADPKD by imaging (23). The criteria for 
diagnosis varies, based upon age and whether family history is ADPKD positive. MR 
imaging is commonly used for monitoring disease progression, since MR imaging is 
more sensitive than ultrasound. Although genetic testing is rarely performed in routine 
clinical practice, it may be helpful in cases of atypical renal imaging findings or renal 
failure without significant kidney enlargement (20).
Symptoms
Clinical manifestations are often directly related to the degree of enlargement of the 
polycystic kidneys. Cyst growth often starts already in utero. Data from the Consortium 
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of Radiologic Imaging Studies to assess the Progression of Polycystic Kidney Disease 
(CRISP) showed that the annual increase in total kidney volume is on average 5 to 6% 
per year (18, 24). Most patients maintain their renal function until the fourth to sixth 
decade, despite of cyst growth. The kidneys are often significantly enlarged by the 
time renal function starts to decline. When renal function starts to drop, the average 
rate of eGFR decline is 1.6 to 5.0 mL/min/year (18).
Another early renal manifestation is hypertension that has a prevalence of 50% of 
patients aged 20-34 years and up to 100% in patients with ESRD (25). Factors proposed 
to contribute to hypertension in ADPKD are activation of the renin angiotensin 
system, increased sympathetic nerve activity and plasma endothelin-1 concentration 
(26). Since hypertension could lead to renal function decline and predisposes to 
cardiovascular disease, adequate therapy is indicated. First line treatment is blockade 
of the Renin-Angiotensin System, because of the alleged activation of this system in 
ADPKD. However, superiority of RAS blockers over other blood pressure lowering 
agents has never formally been tested. Furthermore ADPKD patients may have 
other complications associated with the disease e.g. cyst infections, cyst bleedings, 
renal stones, cardiac valve abnormalities, abdominal wall herniations and intracranial 
aneurysms. Cysts can also be formed extra-renal, with a high prevalence in the liver (up 
to 94%) (7), and in rare cases in the pancreas, seminal vesicles and the brain (4).
The majority of patients also experience pain and polyuria, both symptoms that are 
not always recognized by clinicians. Pain in ADPKD can be classified as acute or chronic. 
Acute severe pain is relatively uncommon. Data from the TEMPO 3:4 trial suggest an 
average incidence of clinically significant acute pain episodes of 7 per 100 person years 
in untreated patients (27, 28). In contrast, chronic pain is very common in patients with 
ADPKD with an estimated prevalence of 60% (29, 30). A subanalysis of the HALT trial 
showed that chronic pain even in ADPKD patients with retained renal function is often 
severe and leads to use of analgesic drugs in 28.0%, sleep disturbances in 16.8% and 
impacts physical activity and relationships with others in 20.8% (30). Thus, chronic pain 
has a major effect on physical and social functioning in many patients with ADPKD. 
Another under-recognized symptom is polyuria, that is caused by an impaired 
urinary concentrating capacity. The mechanism behind this concentrating defect is not 
fully understood, although probably abnormalities in the renal medullary architecture, 
due to cyst formation and expansion, play an important role. In a previous study from 
our group, it was found that already in early stage disease this impaired maximal 
urine concentrating capacity results in increased plasma osmolality and vasopressin 
levels during water deprivation, in comparison with healthy controls (31). Vasopressin 




increases. Vasopressin subsequently binds to the V2 receptor of the collecting ducts, 
which stimulates water reabsorption by migration of aquaporin-2 to the apical cell 
membrane (32). In addition, vasopressin has deleterious effects in ADPKD as it 
increases intracellular cAMP, which promotes cell proliferation and cyst formation (33). 
Indeed, animal models and a large randomized controlled trial showed that blocking 
the vasopressin V2 receptor reduces the rate of cyst growth and renal function loss (22, 
27, 34, 35).
Finally, for patients, the diagnosis ADPKD could also have a strong physical and 
psychological impact (36-38). Patients are monitored in hospitals during their lifetime 
and deal with the uncertainty about the eventual need to become dependent of renal 
replacement therapy. Furthermore in case of family planning, difficult decisions have 
to be made about testing in case subjects with a positive family history have not been 
screened yet, and there may be concerns about the consequences of possible genetic 
transmission to children. Managing this burden can be emotionally challenging. 
Indeed, a recent study showed that ADPKD patients experience considerable distress, 
frustration and confusion, especially when they perceive that physicians do not deal 
appropriately with the impact of ADPKD on their daily life (36). Patients report also 
feelings of shame and guilt because of their physical limitations, inability to work and 
the invisibility of pain (37). ADPKD-related pain can be described as invalidating insofar 
that it affects their daily living, whilst the lack of effective pain therapies can increase 
their frustrations. These psychological aspects can lead to depression and anxiety and 
there is evidence that in ADPKD patients, indeed, depression and anxiety are more 
common than in the general population (38). Early identification of these problems is 
indicated to induce adequate management and to improve quality of life in ADPKD 
patients. 
Symptomatic therapies
Over the past two decades, various, general renoprotective treatment options have 
been investigated in randomized controlled clinical trials, unfortunately without 
success. In these trials neither the assignment to a low protein diet, nor strict blood 
pressure control or double RAS inhibition reduced the rate of renal function decline 
in ADPKD patients (21, 39-42). Therefore treatment of ADPKD is as yet symptomatic. 
When patients experience pain, it is important to regard it within a biopsychosocial 
model. Careful assessment by obtaining a detailed history, physical examination and 
imaging techniques are necessary to identify the cause of pain, and interventions 
should be directed towards these causes. Various conservative and pharmacological 
options are available (43). In case analgesics do not achieve sufficient pain relief, several 
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minimal invasive procedures, such as cyst aspiration, cyst fenestration or nerve blocks 
can be performed. Surgical nephrectomy is the last option, because it is a difficult 
decision to remove a functioning kidney in subjects with a disease that is known to be 
progressive and can lead to ESRD. 
Disease modifying therapies
Several disease specific therapies have been investigated in ADPKD. Since animal 
experiments with mTOR-inhibitors were encouraging, three studies, of which one 
large RCT, investigated the effect of mTOR-inhibitors in ADPKD patients (44-46). In 
all studies, mTOR-inhibitors had no effect on the rate of decline in renal function. 
Therefore it is concluded that this therapy is not useful in ADPKD patients to slow 
disease progression. 
Another promising treatment option is inhibition of the enzyme adenylyl cyclase 
by stimulation of the somatostatin SSR2 receptor. In animal studies as well as in human 
studies, stimulation of the somatostatin receptor led to reduced cyst growth (47-49). In 
a smaller randomized controlled trial of 12 months duration, the efficacy of Octreotide, 
a somatostatin analogue, was investigated in 24 ADPKD patients and 8 polycystic liver 
disease patients (48). In this study, mean liver volume decreased compared to baseline 
with Octreotide, whereas it increased slightly in the placebo group (-4.95% vs. +0.92%, 
p=0.048). Total kidney volume was stable on Octreotide, but increased in the placebo 
group (+0.25% vs. +8.61%, p=0.045). Renal function decreased in both treatment 
groups (-3.5 vs. -5.1 mL/min/1.73m2, p=1.0). Although these data are encouraging, firm 
conclusions regarding efficacy cannot be drawn because of the short duration of the 
trial and the relatively small population that was included. A larger, yet still relatively 
small randomized control trial was performed, including 75 ADPKD patients with 
preserved renal function, the ALADIN trial (49). This study suggested that somatostatin 
analogues may act renoprotective. A significant difference in change in total kidney 
volume was found at 1 year, but after 3 years of treatment the effect was no longer 
significant. Change in renal function from baseline to 3 years of treatment was also 
not significantly different between Octreotide and placebo treated patients, but the 
difference in change in renal function between year 1 and 3 was highly significant 
between both treatment groups, favoring Octreotide. It is known from literature 
that somatostatin analogues cause an acute decrease in eGFR, because an increase 
in somatostatin levels leads to vasoconstriction of the afferent artery (50). This may 
be explain why the investigators of the ALADIN trial found a significant difference in 
change in renal function on treatment (year 1 and 3) between both treatment groups, 




year 3. Additionally, in the ALADIN trial, there were clinically relevant differences in 
baseline characteristics between both treatment group favoring the somatostatin 
analogue. Therefore, the results of this study are difficult to interpret. 
Administration of somatostatin analogues is generally well tolerated. These agents 
play a role in bile release and patients can experience gastro-intestinal side effects, e.g. 
diarrhea, flatulence, abdominal pain and hypoglycaemia. These symptoms are often 
experienced only after the first injections caused by a direct increase in somatostatin 
levels, and are in most patients not a problem because after 3-4 injections patients will 
have reached a steady state concentration of somatostatin levels (48, 49).
Since the data of the ALADIN study are difficult to interpret, there is a need for 
a large RCT to investigate whether somatostatin analogues are effective to reduce 
the rate of disease progression in ADPKD. For this aim our research group designed 
the DIPAK-1 study to examine the efficacy of the somatostatin analogue Lanreotide 
to preserve kidney function in 300 ADPKD patients (51). It is the first large scale 
randomized clinical trial that will investigate the efficacy of a somatostatin analogue 
for renoprotection in ADPKD. It is expected that at the end of 2017 the results will 
become available.
Another therapeutic treatment option is inhibition of the enzyme adenylyl cyclase 
by blockade of the vasopressin V2 receptor. The TEMPO 3:4 trial publication showed 
for the first time in ADPKD patients in a randomized controlled clinical trial setting 
renoprotective effects of an intervention (27). The TEMPO 3:4 trial was a prospective, 
blinded, randomized, controlled trial in 1445 ADPKD patients with a total kidney volume 
>750 mL and preserved renal function. During 3 years of follow-up the vasopressin V2 
receptor antagonist tolvaptan decreased the rate of growth in total kidney volume 
with 49% and the rate of eGFR loss with 26%. The major side effect was that, due 
to its aquaretic effect, tolvaptan causes polyuria that sometimes can be severe (up 
to 6-8 liters per day). Based on these data tolvaptan has recently been approved 
in Japan, Canada and Europe for the indication of slowing disease progressing in 
ADPKD patients, whereas the Food and Drug Authorization in the United States had 
requested additional clinical evidence. 
Outline of the thesis
ADPKD patients may suffer from other symptoms beyond growth in renal volume and 
decline in renal function. The majority of patients also experience two other clinical 
manifestations, i.e. pain and polyuria, which often receive too little attention from 
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clinicians. It is important to adequately respond to ADPKD patients who experience 
pain and polyuria, because these symptoms can have a negative impact on a patient’s 
quality of life. It should also be noted that polyuria will become a more prominent 
manifestation in ADPKD patients, since tolvaptan, that has recently been approved for 
the indication to slow disease progression by the European Medicines Agency, leads 
to polyuria up to 6-8 liters per day because of its aquaretic effect. Because pain and 
polyuria are often neglected, this thesis aims to investigate and discuss these symptoms 
in more detail. The goal of the first part of this thesis (Chapters 2-7) is to analyze pain 
in ADPKD patients, which, when under-treated, can lead to distress and frustration, 
especially when the patients perceive that physicians do not deal appropriately with 
the impact of their pain complaints. In addition, it includes a comprehensive overview 
of potential new pain therapies in ADPKD. In part II (Chapters 8-10) polyuria caused by 
impaired urinary concentrating capacity is evaluated and discussed. At the moment, 
many clinicians are not aware of the impact of this condition which may have a role in 
the pathophysiology of disease progression. 
I. Pain in ADPKD
During lifetime kidney and liver volume increase, leading to distension of the renal and 
hepatic capsules, and compression of adjacent organs (52). Consequently, a substantial 
proportion of ADPKD patients suffer from pain and gastrointestinal symptoms, such as 
abdominal fullness and early satiety (20, 30, 43, 53). There is an ongoing debate if and 
how kidney and liver volume are associated with pain and gastrointestinal symptoms 
patients (30, 54-57). Another factor that potentially affects symptom burden is gender. 
To our knowledge, it has not been investigated whether higher symptom burden in 
females with ADPKD is caused by differences in reporting by sex in general, or by 
differences in kidney and/or liver size between both sexes. Given these considerations, 
it is investigated in a large cohort of ADPKD patients whether combined kidney and 
liver volume is more strongly associated with ADPKD-related pain and gastrointestinal 
symptoms than kidney or liver volume alone, and secondly whether there is a 
differences in the strength of this association between males and females (Chapter 2).
Symptom burden in ADPKD is multifactorial and other factors, in addition to organ 
volume, may contribute (55). Potential other determinants may include comorbidity, 
such as a history of urinary tract infection, renal cyst infection, liver cyst infection and 
macroscopic hematuria. In case an ADPKD patient experiences acute pain and fever, 
the diagnosis cyst infection should be considered. Cyst infections in ADPKD are often 
difficult to treat and may lead to hospitalization and even mortality (58, 59). At this 




of renal cyst infection in ADPKD patients (20). Chapter 3 tries to resolve this gap in 
knowledge, by performing a systematic review identifying all reports describing 
renal cyst infections in individual ADPKD patients. Based on these data, treatment 
preferences and potential factors that could affect treatment outcome are identified.
Pain in ADPKD is arbitrarily classified as acute or chronic. Recently the vasopressin 
V2 receptor antagonist tolvaptan has been approved in Europe for the indication to 
slow disease progression in ADPKD. The authors of the original paper suggested that 
tolvaptan use may be associated with a reduction in clinical progression as assessed 
by its key secondary composite endpoint through a reduction of ADPKD-related 
clinical events (27). This outcome was driven by two components of the composite, 
time to decline in kidney function and time to clinically significant renal pain events. 
In Chapter 4 this last finding is explored more closely. The association of ADPKD 
clinical characteristics (such as history of renal pain, infection, renal stones or hematuria 
at baseline) with the incidence of acute renal pain events during the 3-year trial is 
investigated. Furthermore, the effect of tolvaptan use on incidence of renal pain events 
is analyzed and the possible mechanisms by which tolvaptan reduced their incidence 
are explored. 
In contrast to acute pain, chronic pain is very common in patients with ADPKD 
with an estimated prevalence of 60% (29, 30). Chronic pain in ADPKD can have various 
causes and may be difficult to manage. Several algorithms for pain management in 
ADPKD have been published and indicated that as a last resort, nephrectomy can 
be performed for pain relief in patients with refractory renal pain (60-62). This is a 
difficult decision, removing a functioning kidney in patients with a disease that often 
leads to end-stage renal disease. Therefore there is a need for effective and less 
invasive therapies for chronic pain in ADPKD. Chapter 5 reports a potential new 
treatment option, i.e. catheter based renal denervation, for chronic pain in ADPKD. 
Renal denervation has already been performed by laparoscopic and thoracoscopic 
procedures with satisfactory results in ADPKD patients with chronic pain, but these 
invasive techniques are difficult to perform. Recently a catheter-based percutaneous 
transluminal method has been introduced to ablate efferent and afferent renal 
sympathetic nerve fibres. This procedure may be a simple and effective alternative. 
In Chapter 6 an overview of pathophysiological mechanisms that can lead to 
pain and the sensory innervation of abdominal organs (including the kidneys and the 
liver) is provided. Based on pathophysiological considerations and evidence derived 
from literature an argumentative stepwise multidisciplinary approach for the effective 
management of chronic pain in ADPKD is proposed. In this approach the potential role 
for minimal invasive nerve blocks is discussed. From a theoretical point of view a celiac 
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plexus block, a block of the splanchnic nerves and catheter-based renal denervation 
are attractive options in selected cases, but further research is needed to determine 
the efficacy and their exact role in the management of refractory chronic pain in ADPKD 
patients. So, this stepwise multidisciplinary approach was applied in a large series of 
patients with refractory chronic ADPKD-related pain (Chapter 7).
II. Polyuria in ADPKD 
At the moment, little attention is paid to polyuria in ADPKD patients. Impaired urine 
concentrating capacity resulting in polyuria deserves more attention, since it may have 
potentially negative consequences in the pathophysiology of disease progression (63, 
64). The mechanism leading to decreased urine concentrating capacity is not fully 
understood, although probably abnormalities in the renal medullary architecture, due 
to cyst formation and expansion, play an important role. Impaired urine concentrating 
capacity is accompanied by increased plasma osmolality and vasopressin levels. 
In ADPKD vasopressin has deleterious effects as it increases intracellular cAMP, 
which promotes cell proliferation and cyst formation (33). In addition to blocking of 
the vasopressin V2 receptor, drinking a sufficient volume of water can also reduce 
vasopressin concentration. Increasing water intake could therefore be an alternative 
to medical treatment with a V2 receptor antagonist to ameliorate disease progression 
in ADPKD. 
In a previous study in ADPKD patients, it was found that already in the early stages 
of disease there is an impaired maximal urine concentrating capacity in comparison 
to healthy controls, which is accompanied by increased plasma osmolality and 
vasopressin levels during water deprivation (31). It is hypothesized that in later stage 
of ADPKD, patients have a more severely impaired urine concentrating capacity in 
comparison to other patients with chronic kidney disease at a similar level of kidney 
function, with consequently an enhanced vasopressin response to water deprivation 
with higher circulating vasopressin concentrations (65, 66). To test this hypothesis, 
a water deprivation test was performed in ADPKD and non-ADPKD patients with 
impaired kidney function (Chapter 8).
In Chapter 9 the clinical implications of an impaired urinary concentrating 
capacity are discussed. As mentioned earlier, an increased water intake could be an 
alternative to medical treatment with a V2 receptor antagonist to ameliorate disease 
progression in ADPKD. For clinicians, the question arises which ADPKD patients they 
should advise to increase their water intake, and what volume of fluid they should 
drink. In this respect, measuring urine osmolality could be of help (67-70). It is generally 




than plasma osmolality, reflects adequate suppression of vasopressin (68, 69). This 
chapter describes whether urine and plasma osmolality can be used to identify ADPKD 
patients with a high vasopressin concentration that are at risk for a more rapid rate of 
kidney function decline during follow-up (52).
Due to its aquaretic effect tolvaptan, a V2 receptor antagonist, causes polyuria that 
sometimes can be severe. In every patient with polyuria (e.g. a patient with diabetes 
insipidus or psychogenic polydipsia) infrequent voiding can lead to an increase in 
bladder volume, high bladder pressure, ureter dilatation and reflux, with consequently 
renal function loss (71-73). These patients are, therefore, usually advised to void 
frequently to prevent these potential negative consequences (71). ADPKD patients 
using tolvaptan have potentially a risk to develop similar problems. In a series of 
ADPKD patients that was started on tolvaptan or placebo in a trial setting, MR imaging 
was performed routinely for total kidney volume assessment. These MR images were 
used in Chapter 10 to investigate the effect of tolvaptan induced polyuria on ureter 
diameter.
Finally, in the General discussion (Chapter 11) the main findings of the individual 
chapters are summarized and their potential consequences for daily practice are 
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